These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 31991225)

  • 1. Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.
    Domblides C; Leroy K; Monnet I; Mazières J; Barlesi F; Gounant V; Baldacci S; Mennecier B; Toffart AC; Audigier-Valette C; Doucet L; Giroux-Leprieur E; Guisier F; Ricordel C; Molinier O; Perol M; Pichon E; Robinet G; Templement-Grangerat D; Ruppert AM; Rabbe N; Antoine M; Wislez M
    J Thorac Oncol; 2020 May; 15(5):860-866. PubMed ID: 31991225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
    Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Yoh K; Matsumoto S; Furuya N; Nishino K; Miyamoto S; Oizumi S; Okamoto N; Itani H; Kuyama S; Nakamura A; Nishi K; Fukuda I; Tsuta K; Hayashi Y; Motoi N; Ishii G; Goto K
    Lung Cancer; 2021 Sep; 159():128-134. PubMed ID: 34333203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.
    Babacan NA; Pina IB; Signorelli D; Prelaj A; Garassino MC; Tanvetyanon T
    Clin Lung Cancer; 2020 Sep; 21(5):e456-e463. PubMed ID: 32265109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
    Shinno Y; Yoshida A; Masuda K; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y
    Clin Lung Cancer; 2022 Jul; 23(5):386-392. PubMed ID: 35618627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
    Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y
    Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
    J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.
    Qian X; Wang Y; Liu F; Yuan Y; Fang C; Zhang X; Yuan S; Chen R; Yu B; Wang T; Yin Y; Li Y
    Front Immunol; 2022; 13():956982. PubMed ID: 36389780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
    Uruga H; Mino-Kenudson M
    Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
    Dudnik E; Peled N; Nechushtan H; Wollner M; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadari N; Urban D; Mishaeli M; Zer A; Allen AM; Rabinovich NM; Rotem O; Kuznetsov T; Shochat T; Roisman LC; Bar J;
    J Thorac Oncol; 2018 Aug; 13(8):1128-1137. PubMed ID: 29723688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
    Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
    Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.
    Yarchoan M; Albacker LA; Hopkins AC; Montesion M; Murugesan K; Vithayathil TT; Zaidi N; Azad NS; Laheru DA; Frampton GM; Jaffee EM
    JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30895946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
    Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
    Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data.
    Yan N; Zhang H; Shen S; Guo S; Li X
    BMC Cancer; 2024 Feb; 24(1):178. PubMed ID: 38317126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.